Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7STF

Structure of KRAS G12V/HLA-A*03:01 in complex with antibody fragment V2

Summary for 7STF
Entry DOI10.2210/pdb7stf/pdb
EMDB information25427
DescriptorIgG, Fab Heavy Chain V2, KRAS G12V (7-16), IgG, Fab Light Chain V2, ... (5 entities in total)
Functional Keywordscomplex, mhc-i, kras, hla-a3, immune system
Biological sourceHomo sapiens (human)
More
Total number of polymer chains5
Total formula weight92139.32
Authors
Wright, K.M.,Gabelli, S.B.,Miller, M. (deposition date: 2021-11-12, release date: 2023-05-31, Last modification date: 2024-11-20)
Primary citationWright, K.M.,DiNapoli, S.R.,Miller, M.S.,Aitana Azurmendi, P.,Zhao, X.,Yu, Z.,Chakrabarti, M.,Shi, W.,Douglass, J.,Hwang, M.S.,Hsiue, E.H.,Mog, B.J.,Pearlman, A.H.,Paul, S.,Konig, M.F.,Pardoll, D.M.,Bettegowda, C.,Papadopoulos, N.,Kinzler, K.W.,Vogelstein, B.,Zhou, S.,Gabelli, S.B.
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.
Nat Commun, 14:5063-5063, 2023
Cited by
PubMed Abstract: Specificity remains a major challenge to current therapeutic strategies for cancer. Mutation associated neoantigens (MANAs) are products of genetic alterations, making them highly specific therapeutic targets. MANAs are HLA-presented (pHLA) peptides derived from intracellular mutant proteins that are otherwise inaccessible to antibody-based therapeutics. Here, we describe the cryo-EM structure of an antibody-MANA pHLA complex. Specifically, we determine a TCR mimic (TCRm) antibody bound to its MANA target, the KRAS peptide presented by HLA-A*03:01. Hydrophobic residues appear to account for the specificity of the mutant G12V residue. We also determine the structure of the wild-type G12 peptide bound to HLA-A*03:01, using X-ray crystallography. Based on these structures, we perform screens to validate the key residues required for peptide specificity. These experiments led us to a model for discrimination between the mutant and the wild-type peptides presented on HLA-A*03:01 based exclusively on hydrophobic interactions.
PubMed: 37604828
DOI: 10.1038/s41467-023-40821-w
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3.14 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon